Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Clinical trial NCT04056910 · COMPLETED
Trial details
- NCT number
- NCT04056910
- Sponsor
- Jason J. Luke, MD
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-20
- Primary completion
- 2023-11-13
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.